沙利度胺用于预防化疗患者恶心、呕吐的临床疗效分析

Analysis of Clinical Curative Effect of Thalidomide in Preventing the Nausea and Vomiting of Chemotherapy Patients

目的通过研究探讨沙利度胺用于预防化疗患者恶心、呕吐的临床疗效以及用法用量等方面的问题。方法选取该院从2016年1—10月期间收治的肿瘤患者60例为研究对象,随机的分成两组,即对照组和观察组各30例患者。对照组30例患者采用常规化疗及5-HT3受体拮抗剂联合治疗。观察组30例患者则在对照组的基础上加用沙利度胺联合治疗。该次研究两组患者的治疗方案均为21~28 d为1个疗程,在该次研究进行2个疗程后,对两组患者的恶心、呕吐的控制率、患者的生活质量以及患者发生的不良反应情况进行相应的统计分析,观察沙利度胺对化疗患者恶心、呕吐的临床疗效。结果通过研究发现,实验组和对照组控制化疗所致恶心的有效率分别为90.0%和50.0%,控制呕吐的有效率为93.3%和60.0%,实验组均高于对照组(P<0.01)。结论沙利度胺具有预防化疗病人恶心、呕吐的临床疗效显著,不良反应低,价格低廉等优势,值得在临床上推广使用。

Objective To research the clinical curative effect and dosage of thalidomide in preventing the nausea and vomiting of chemotherapy patients. Methods Convenient selection 60 cases of tumor patients admitted and treated in our hospital from January 2016 to October 2016 were selected as the research objects and randomly divided into two groups with 30 cases in each, the control group adopted the routine chemotherapy and 5-HT3 receptor antagonist, while the observation group adopted the thalidomide on the basis of the control group, and the treatment course was between 21 d to 28 d, and after 2 treatment courses, the controlling rate of nausea and vomiting, quality of life of patients and adverse reactions of patients were analyzed and counted, and the clinical curative effect of thalidomide on the nausea and vomiting of chemotherapy patients was observed. Results The research showed that the effective rate of controlling nausea caused by the chemotherapy was respectively 90.0% and 50.0% in the experimental group and in the control group, and the effective rate of controlling vomiting in the experimental group was higher than that in the control group（93.3% vs 60.0%）（P0.01）. Conclusion The clinical curative effect of thalidomide in preventing the nausea and vomiting of chemotherapy patients is obvious with low adverse effect and low price, which is worth promotion and application in clinic.